141 related articles for article (PubMed ID: 27061401)
21. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
[TBL] [Abstract][Full Text] [Related]
22. The fallacy of single-agent chemotherapy for cancer.
Friedman HS; Maxwell J
J Clin Oncol; 2007 Aug; 25(23):3550; author reply 3550-1. PubMed ID: 17687162
[No Abstract] [Full Text] [Related]
23. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Lee DY; Chunta JL; Park SS; Huang J; Martinez AA; Grills IS; Krueger SA; Wilson GD; Marples B
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):978-85. PubMed ID: 23845846
[TBL] [Abstract][Full Text] [Related]
24. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma.
Galldiks N; Kracht LW; Burghaus L; Ullrich RT; Backes H; Brunn A; Heiss WD; Jacobs AH
Mol Imaging; 2010 Feb; 9(1):40-6. PubMed ID: 20128997
[TBL] [Abstract][Full Text] [Related]
25. In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Al-Saffar NMS; Agliano A; Marshall LV; Jackson LE; Balarajah G; Sidhu J; Clarke PA; Jones C; Workman P; Pearson ADJ; Leach MO
PLoS One; 2017; 12(7):e0180263. PubMed ID: 28704425
[TBL] [Abstract][Full Text] [Related]
26. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
[TBL] [Abstract][Full Text] [Related]
27. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
[TBL] [Abstract][Full Text] [Related]
28. Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.
Dyke JP; Sanelli PC; Voss HU; Serventi JV; Stieg PE; Schwartz TH; Ballon D; Shungu DC; Pannullo SC
J Neurooncol; 2007 Mar; 82(1):103-10. PubMed ID: 17031552
[TBL] [Abstract][Full Text] [Related]
29. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
[TBL] [Abstract][Full Text] [Related]
30. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
31. Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
Villamañan L; Martínez-Escardó L; Arús C; Yuste VJ; Candiota AP
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810611
[TBL] [Abstract][Full Text] [Related]
32. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.
Mangla R; Singh G; Ziegelitz D; Milano MT; Korones DN; Zhong J; Ekholm SE
Radiology; 2010 Aug; 256(2):575-84. PubMed ID: 20529987
[TBL] [Abstract][Full Text] [Related]
33. Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Kang DW; Hwang WC; Noh YN; Park KS; Min DS
J Pathol; 2020 Nov; 252(3):304-316. PubMed ID: 32725633
[TBL] [Abstract][Full Text] [Related]
34. Hierarchical non-negative matrix factorization (hNMF): a tissue pattern differentiation method for glioblastoma multiforme diagnosis using MRSI.
Li Y; Sima DM; Cauter SV; Croitor Sava AR; Himmelreich U; Pi Y; Van Huffel S
NMR Biomed; 2013 Mar; 26(3):307-19. PubMed ID: 22972709
[TBL] [Abstract][Full Text] [Related]
35. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
[TBL] [Abstract][Full Text] [Related]
36. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
37. Long-term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide in Patients with Glioblastoma (SV3 Study).
Rivoirard R; Falk AT; Chargari C; Guy JB; Mery B; Nuti C; Peoc'h M; Forest F; Garin C; Adjabi A; Hoarau D; Kawaye S; Almokhles H; Fournel P; Magné N
Clin Oncol (R Coll Radiol); 2015 Aug; 27(8):486-7. PubMed ID: 25963856
[No Abstract] [Full Text] [Related]
38. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
39. An advanced MRI and MRSI data fusion scheme for enhancing unsupervised brain tumor differentiation.
Li Y; Liu X; Wei F; Sima DM; Van Cauter S; Himmelreich U; Pi Y; Hu G; Yao Y; Van Huffel S
Comput Biol Med; 2017 Feb; 81():121-129. PubMed ID: 28061367
[TBL] [Abstract][Full Text] [Related]
40. Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Kim C; Kim HS; Shim WH; Choi CG; Kim SJ; Kim JH
Radiology; 2017 Jan; 282(1):212-221. PubMed ID: 27428890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
